EBITDA Margin: Earnings before interest, taxes, depreciation and amortization as a portion of total revenue. Calculated as: EBITDA / Total Revenues
Cue Biopharma, Inc. (CUE) had EBITDA Margin of -93.82% for the most recently reported fiscal year, ending 2025-12-31.
| Income Statement Financials | |
$27.47M |
|
$-26.60M |
|
-- |
|
$27.47M |
|
$54.02M |
|
$-26.55M |
|
$0.45M |
|
$-26.10M |
|
$-26.10M |
|
$-26.60M |
|
$-26.60M |
|
$-26.60M |
|
$-26.60M |
|
$-26.55M |
|
$-25.77M |
|
94.73M |
|
94.73M |
|
$-0.28 |
|
$-0.28 |
|
| Balance Sheet Financials | |
$36.98M |
|
$0.24M |
|
$5.23M |
|
$42.21M |
|
$13.49M |
|
-- |
|
$2.29M |
|
$15.78M |
|
$26.43M |
|
$26.43M |
|
$26.43M |
|
96.62M |
|
| Cash Flow Statement Financials | |
$-21.69M |
|
$0.07M |
|
$26.29M |
|
$22.61M |
|
$27.29M |
|
$4.68M |
|
$4.74M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
2.74 |
|
-- |
|
-- |
|
-- |
|
-- |
|
100.00% |
|
-96.67% |
|
-96.67% |
|
|
EBITDA Margin |
-93.82% |
-95.03% |
|
-96.85% |
|
$-21.82M |
|
-- |
|
-- |
|
-- |
|
0.65 |
|
-- |
|
4.95 |
|
73.70 |
|
-100.64% |
|
-100.64% |
|
-63.02% |
|
-100.64% |
|
$0.27 |
|
$-0.23 |
|
$-0.23 |
|